Canagliflozin and Stroke in Type 2 Diabetes Mellitus
نویسندگان
چکیده
منابع مشابه
Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
Current guidelines for treatment of type 2 diabetes mellitus (T2DM) indicate a patient-centered approach that should go beyond glycemic control. Of the many antihyperglycemic agents available for treatment of T2DM, sodium-glucose cotransporter 2 (SGLT2) inhibitors offer the advantages of reduced glycated hemoglobin (A1C), body weight (BW), and systolic blood pressure (SBP) and are associated wi...
متن کاملPrevalence of Onychomycosis in Type 2 Diabetes Mellitus
Abstract Background and Objective: Onychomycosis is a fungal nail infection causing ulcers, diabetic foot and enhance nail infection. This study was designed to evaluate the prevalence of onychomycosis in type II diabetes. Material and methods: This descriptive-analytic study was conducted on 300 diabetic patients selected randomly among those referred to Panje Azar endocrinology clinic. ...
متن کاملEfficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates
AIMS Patients with type 2 diabetes mellitus (T2DM) have increased risk of adverse events (AEs; e.g. dehydration, hypoglycaemia) in hot weather. This analysis assessed the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, in patients with T2DM who live in hot climates. METHODS This post hoc analysis evaluated patients with T2DM using pooled data from fo...
متن کاملSexual Dysfunction in Women with Type 2 Diabetes Mellitus
Background: Sexual dysfunction (SD) is one of the important problems in diabetic patients.The present study aimed to determine the prevalence of sexual problems in Iranian women with type 2 diabetes mellitus. Methods: A cross-sectional study was conducted among type 2 diabetic women who visited two outpatient endocrine clinics, namely Imam Hospital and Tuba clinic (Sari, Iran) in 2012. Patients...
متن کاملPharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
INTRODUCTION Canagliflozin is a sodium glucose co-transporter 2 inhibitor approved worldwide for the treatment of patients with type 2 diabetes mellitus (T2DM). The present study evaluated pharmacokinetics, pharmacodynamics, and safety of canagliflozin in Japanese patients with T2DM. METHODS Canagliflozin, at doses of 25, 100, 200, or 400 mg, was administered as a single dose and, after a was...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Stroke
سال: 2019
ISSN: 0039-2499,1524-4628
DOI: 10.1161/strokeaha.118.023009